Physician profile
Pranav Patel
NPI 1548689987
$2,098.55
in general payments reported to CMS, 2019-2025
15 companies · $679 in 2025
The $679 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.94 · 2023: $561 · 2024: $845 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.11 | 2024-2025 | |
| Medtronic, INC. | $291.10 | 2023-2025 | Manoscan, Bravo, Het |
| Takeda Pharmaceuticals U.S.A., INC. | $190.11 | 2022-2025 | Gattex, Eohilia |
| Fujifilm Healthcare Americas Corporation | $160.00 | 2023-2024 | |
| Boston Scientific Corporation | $148.36 | 2023-2025 | General - Therapies |
| Janssen Biotech, INC. | $127.23 | 2025 | Tremfya |
| Gilead Sciences, INC. | $124.02 | 2024 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $121.40 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $111.94 | 2025 | Voquezna |
| Genzyme Corporation | $104.47 | 2023 | |
| Madrigal Pharmaceuticals | $78.54 | 2024 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $54.20 | 2025 | Tremfya |
| Ferring Pharmaceuticals INC. | $53.71 | 2023 | Rebyota |
| Steris Corporation | $23.26 | 2025 | |
| Ardelyx, INC. | $20.10 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.